GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease
References
- Kosmalski M., Ziółkowska S., Czarny P., Szemraj J., Pietras T.: The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Med., 2022; 11: 1375
- Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol., 2013; 58: 593–608
- Younossi Z. M., Golabi P., de Avila L., Paik J. M., Srishord M., Fukui N., Qiu Y., Burns L., Afendy A., & Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol., 2019; 71: 793–801
- Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006; 368: 1696–705
- Filippatos T.D., Panagiotopoulou T.V., Elisaf M.S.. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud RDS., 2014; 11: 202
- He Z., Gao Y., Lieu L., Afrin S., Cao J., Michael N.J., Dong Y., Sun J., Guo H., Williams K.W. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons—Implications for energy balance and glucose control. Mol Metab., 2019; 28: 120–134
- Wadden T.A., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., Aronne L.; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes., 2013; 37: 1443–51
- Monami M., Dicembrini I., Marchionni N., Rotella C.M., Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res., 2012: 672658
- Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al. STEP 1 Study Group: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med., 2021; 384: 989–1002
- Davies M., Færch L., Jeppesen O.K., Pakseresht A., Pedersen S.D., Perreault L., Rosenstock J., Shimomura I., Viljoen A., Wadden T.A., et al., STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet., 2021; 397: 971–984
- Rubino D., Abrahamsson N., Davies M., Hesse D., Greenway F.L., Jensen C., Lingvay I., Mosenzon O., Rosenstock J., Rubio M.A., et al., STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults With over-weight or obesity: The STEP 4 randomized clinical trial. JAMA., 2021; 325: 1414–1425
- Kadowaki T., Isendahl J., Khalid U., Lee S.Y., Nishida T., Ogawa W., Tobe K., Yamauchi T., Lim S., STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol., 2022 10: 193–206
- Rubino D.M., Greenway F.L., Khalid U., O’Neil P.M., Rosenstock J., Sørrig R., Wadden T.A., Wizert A., Garvey W.T., STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults With overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA., 2022; 327: 138–150
- Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity, Available at:
https://www.prnewswire.com/news-releases/wegovy-demonstrated-significant-and-sustained-weight-loss-in-two-year-study-in-adults-with-obesity-301417583.html (Accessed September 26, 2022) - Wadden T.A., Bailey T.S., Billings L.K., Davies M., Frias J.P., Koroleva A., Lingvay I., O’Neil P.M., Rubino D.M., Skovgaard D., et al., STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with over-weight or obesity: The STEP 3 Randomized Clinical Trial. JAMA., 2021; 325: 1403–1413
- Jabbour S.A., Frías J.P., Guja C., Hardy E., Ahmed A., Öhman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. czerwiec 2018; 20: 1515–9
- Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: Review of management for primary care providers. Mayo Clin Proc., wrzesień 2022; 97: 1700–16
- Kosmalski M., Drzewoski J., Szymczak-Pajor I., Zieleniak A., Mikołajczyk-Solińska M., Kasznicki J., Śliwińska A.. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines, 2022; 10: 2253
- Cichoż-Lach H. Obesity and non-alcoholic fatty liver disease. In: Clinical Obesitology. Bielsko-Biała: Alfa-Medica Press; 2021: 206–15
- Ghosal S., Datta D., Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 11 listopad 2021; 11: 22063
- Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin., 2008; 24: 275–286
- Armstrong M.J., Houlihan D.D., Rowe I.A., Clausen W.H., Elbrønd B., Gough S.C., Tomlinson J.W., Newsome P.N. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther., 2013; 37: 234–242
- Jendle J., Nauck M.A., Matthews D.R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B.J., Garber A.J.; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab., 2009; 11: 1163–72
- Petit J.M., Cercueil J.P., Loffroy R., Denimal D., Bouillet B., Fourmont C., Chevallier O., Duvillard L., Vergès B. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab., 2017;102: 407–415
- Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K.; LEAN trial team, Abouda G., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387: 679–690
- Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., Sanyal AJ, Sejling AS, Harrison SA; et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med., 2021; 384: 1113–1124
- Péterfi Z., Szilvásy-Szabó A., Farkas E., Ruska Y., Pyke C., Knudsen L.B., Fekete C. Glucagon-like peptide-1 regulates the proopiomelanocortin neurons of the arcuate nucleus both directly and indirectly via presynaptic action. Neuroendocrinology, 2021; 111: 986–997
- Müller T.D., Finan B., Bloom S.R., D’Alessio D., Drucker D.J., Flatt P.R., Fritsche A., Gribble F., Grill H.J., Habener J.F., et al. Glucagon-like peptide 1 (GLP-1). Mol Metab., 2019; 30: 72–130
- Heppner K.M., Kirigiti M., Secher A., Paulsen S.J., Buckingham R., Pyke C., Knudsen L.B., Vrang N., Grove K.L. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology, 2015; 156: 255–267
- Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP–1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res., 2011; 89: 481–489
- Athauda D., Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today, 2016; 21: 802–818
- Spielman L.J., Gibson D.L., Klegeris A. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. Eur J Cell Biol., 2017; 96: 240–253
- Timper K., Del Río–Martín A., Cremer A.L., Bremser S., Alber J., Giavalisco P., Varela L., Heilinger C., Nolte H., Trifunovic A., et al. GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function. Cell Metab., 2020; 31: 1189–1205.e13
- Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, et al. Central and peripheral GLP–1 systems independently suppress eating. Nat Metab. 2021; 3(2): 258–273.
- Głombik K., Detka J., Budziszewska B. Hormonal regulation of oxidative phosphorylation in the brain in health and disease. Cells, 2021;10: 2937
- Farr O.M., Upadhyay J., Rutagengwa C., DiPrisco B., Ranta Z., Adra A., Bapatla N., Douglas V.P., Douglas K.A.A., Nolen-Doerr E., et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab., 2019; 21: 2459–2464
- Seghieri M., Rebelos E., Gastaldelli A., Astiarraga B.D., Casolaro A., Barsotti E., Pocai A., Nauck M., Muscelli E., Ferrannini E. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia., 2013; 56: 156–161
- Gastaldelli A., Gaggini M., Daniele G., Ciociaro D., Cersosimo E., Tripathy D., Triplitt C., Fox P., Musi N., DeFronzo R., et al. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016; 64: 2028–2037
- Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., Anania F.A. Glucagon–like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010; 51: 1584–1592
- Pyke C., Heller R.S., Kirk R.K., Ørskov C., Reedtz-Runge S., Kaastrup P., Hvelplund A., Bardram L., Calatayud D., Knudsen L.B. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 2014; 155: 1280–1290
- Seghieri M., Christensen A.S., Andersen A., Solini A., Knop F.K., Vilsbøll T. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne), 2018; 9: 649
- Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., Faraci G., Pacetti D., Vivarelli M., Nicolini D., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int., 2011; 31: 1285–1297
- Oliveira F.C.B., Bauer E.J., Ribeiro C.M., Pereira S.A., Beserra B.T.S., Wajner S.M., Maia A.L., Neves F.A.R., Coelho M.S., Amato A.A. Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue. Front Endocrinol (Lausanne). 2022; 12: 803363
- Marín-Juez R., Jong-Raadsen S., Yang S., Spaink H.P. Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish. J Endocrinol., 2014; 222: 229–241
- Lu Y., Jiang Z., Dai H., Miao R., Shu J., Gu H., Liu X., Huang Z., Yang G., Chen A.F., et al. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway. Hepatology. 2018; 67: 1303–1319
- Xu E., Forest M.P., Schwab M., Avramoglu R.K., St-Amand E., Caron A.Z., Bellmann K., Shum M., Voisin G., Paquet M., et al. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ. Hepatology, 2014; 59: 1803–1815
- Yu P., Xu X., Zhang J., Xia X., Xu F., Weng J., Lai X., Shen Y. Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway. Int J Endocrinol., 2019; 19: 1567095
- Kim E.R., Park J.S., Kim J.H., Oh J.Y., Oh I.J., Choi D.H., Lee Y.S., Park I.S., Kim S., Lee D.H., et al. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. Hepatology, 2022; 75: 1523–1538
DOI: https://doi.org/10.2478/ahem-2023-0001 | Journal eISSN: 1732-2693
Language: English
Page range: 1 - 8
Submitted on: Apr 5, 2022
Accepted on: Oct 20, 2022
Published on: Feb 28, 2023
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2023 Kacper Deska, Bartłomiej Bąk, Marcin Kosmalski, Tadeusz Pietras, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.